NCT04582318View on ClinicalTrials.gov

A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 9, 2020

Primary Completion Date

February 18, 2021

Study Completion Date

March 11, 2021

Conditions
SARS-CoV-2 Infection
Interventions
BIOLOGICAL

NGM621

NGM621 will be administered via IV infusion

BIOLOGICAL

Placebo

Placebo will be administered via IV infusion

Trial Locations (1)

Unknown

NGM Clinical Study Site, Brisbane

Sponsors
All Listed Sponsors
lead

NGM Biopharmaceuticals, Inc

INDUSTRY

NCT04582318 - A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19 | Biotech Hunter | Biotech Hunter